April 30th 2025
The FDA has completed its 30-day review of an application for Hepzato in combination with standard of care in liver-dominant metastatic breast cancer.
April 29th 2025
April 25th 2025
March 10th 2025
March 7th 2025
March 6th 2025
March 5th 2025
March 31st 2025
March 3rd 2025
February 23rd 2025